



TEPEZZA[®]
teprotumumab-trbw

Access Roadmap



INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

Please see Important Safety Information inside and accompanying Full Prescribing Information or visit [TEPEZZAhcp.com](https://www.tepezzahcp.com).



1

Gather clinical information on patient's Thyroid Eye Disease (TED) diagnosis

- Download and review the prior authorization (PA) form and requirements from the payor website
- Common requirements are:**
- Clinical Activity Score and severity
 - Onset of symptoms
 - Previous treatments, conditions, or enacted step therapies
 - Provider information and credentials
- Collaborate with referring/co-managing physicians to gather patient history, chart notes, and lab results
 - Gather a letter of medical necessity to proactively include with the PA form



2

Initiate patient enrollment

- Download Patient Enrollment Form (PEF) for Horizon By Your Side at **TEPEZZAhcp.com**
- Discuss the Horizon By Your Side patient support program with your patient and inform them that a Horizon Patient Access Liaison will reach out to them
- Educate your patient on the infusion process and potential side effects of TEPEZZA



3

Review patient's benefits investigation and payor requirements

- Verify your patient's insurance coverage and identify any payor-specific site of care (SOC) requirements
- Work with your patient and Horizon By Your Side to ensure insurance coverage and select an SOC for TEPEZZA administration
- Communicate to the SOC all information about the patient's TED diagnosis and disease severity



4

Coordinate submission of prior authorization with SOC

- Coordinate with the SOC to confirm who submits the PA request to the payor
 - Submit the PA, letter of medical necessity, and any supporting documentation
- In the case of PA denial:**
- Understand the payor's reason for denial and use exact language to craft an appeal letter
 - Gather additional supporting information



Key process tips

- Your patient must complete the PEF to access Horizon By Your Side resources. **Both the patient's signature and healthcare provider's signature are required** to complete the PEF
- Contact your Horizon PAL if you have questions about specific PA requirements

Follow patient treatment after approval

- ❑ Confirm your patient has scheduled their first infusion appointment after PA approval
- ❑ Coordinate patient monitoring/lab work with the SOC and/or co-managing physicians throughout the infusion process including but not limited to:
 - Glucose monitoring
 - Pregnancy
 - Patient weight
 - Hearing Impairment
- ❑ Follow up and document patient reported outcomes throughout the infusion process



Get to know your Horizon team



Specialty Account Manager (SAM): The SAM is your primary point of contact for TEPEZZA. Your SAM provides clinical education and resources to you and your office. In addition, your SAM will connect you to all TEPEZZA team members, as specific needs arise.



Patient Access Liaison (PAL): The PAL provides dedicated, one-on-one support for your patient. They work directly with individual patients to answer non-medical, logistical questions and provide support upon enrollment. Additionally, the PAL educates about navigating insurance processes and accessing treatment on your patient's behalf. The PAL has the expertise and tools to support the patient by educating on patient benefits, prior authorization requirements, payor policies and coding, and claim submissions.



Associate Director, Site of Care Team (ADSOC): Primary Horizon contact for the site of care. The team educates on coding, billing, and payor access and provides product in-servicing.

Horizon offers additional tools to support your office

Visit **TEPEZZAhcp.com** to find multiple resources that aid in the patient access journey

Patient Enrollment Form
 Form ID: PE-001 | Version: 1.0 | Last Updated: 10/2023 | For more information, visit [TEPEZZA.com](https://www.tepezza.com) or call 1-833-469-8333.

Patient Information

Physician Information

Insurance Information

Site of Care Information

Additional Information

Please see Important Safety Information on next page and see Full Prescribing Information at [TEPEZZA.com](https://www.tepezza.com).



Helping you assess site of care options for your patients

Highlighted common sites of care include:

- Physician office
- Hospital outpatient department
- Home infusion
- Independent infusion center

Please see Important Safety Information on back cover and accompanying Full Prescribing Information at [www.TEPEZZA.com](https://www.tepezza.com).

TEPEZZA
teprotumumab-trbw



Horizon By Your Side Patient Enrollment Form (PEF)

Site of Care Guide

Infusion Order Guide

Infusion Order

Patient Information

Physician Information

Medication Order

Lab Orders

The sample infusion order form can be downloaded from the Resource Library at [www.TEPEZZA.com](https://www.tepezza.com).



Infusion Order

Patient Information

Physician Information

Medication Order

Lab Orders

Notes:

1. Patient information must be completed. 2. Copy of the patient's insurance card. 3. Clinical progress notes and history and physical (H&P) to support diagnosis, and 4. Reason for infusion.

TEPEZZA
teprotumumab-trbw



Infusion Order Guide

Infusion Order Form



TEPEZZA and the HORIZON logo are trademarks owned by or licensed to Horizon. All other trademarks are the property of their respective owners.
 © 2023 Horizon Therapeutics plc PA-TEP-US-0014-3 08/23



INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with TEPEZZA. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving TEPEZZA.

Hearing Impairment Including Hearing Loss: TEPEZZA may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients' hearing before, during, and after treatment with TEPEZZA and consider the benefit-risk of treatment with patients.

ADVERSE REACTIONS

The most common adverse reactions (incidence \geq 5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, weight decreased, nail disorders, and menstrual disorders.

Please see Full Prescribing Information or visit TEPEZZAhcp.com for more information.

